Superior Title: Merck & Co., Inc. MarketLine Company Profile. 4/18/2023, p1-79. 79p.

Subject Terms: *HEALTH care industry

Geographic Terms: UNITED States

Company/Entity: MERCK & Co. Inc. 001317064 MRK

Superior Title: Merck & Co., Inc. SWOT Analysis. 4/18/2023, p1-7. 7p.

Subject Terms: *PHARMACEUTICAL industry, *SWOT analysis

Geographic Terms: NEW Jersey

Company/Entity: MERCK & Co. Inc. 001317064 MRK

Superior Title: Merck & Co., Inc. MarketLine Company Profile. 12/14/2022, p1-77. 77p.

Subject Terms: *HEALTH care industry

Geographic Terms: UNITED States

Company/Entity: MERCK & Co. Inc. 001317064 MRK

Superior Title: Merck & Co., Inc. SWOT Analysis. 12/14/2022, p1-7. 7p.

Subject Terms: *PHARMACEUTICAL industry, *SWOT analysis

Geographic Terms: NEW Jersey

Company/Entity: MERCK & Co. Inc. 001317064 MRK

Authors: Janjigian, Yelena Y^1,2 (AUTHOR) janjigiy@mskcc.org, Kawazoe, Akihito³ (AUTHOR), Bai, Yuxian⁴ (AUTHOR), Xu, Jianming⁵ (AUTHOR), Lonardi, Sara⁶ (AUTHOR), Metges, Jean Phillipe⁷ (AUTHOR), Yanez, Patricio⁸ (AUTHOR), Wyrwicz, Lucjan S⁹ (AUTHOR), Shen, Lin¹⁰ (AUTHOR), Ostapenko, Yuriy¹¹ (AUTHOR), Bilici, Mehmet¹² (AUTHOR), Chung, Hyun Cheol¹³ (AUTHOR), Shitara, Kohei³ (AUTHOR), Qin, Shu-Kui¹⁴ (AUTHOR), Van Cutsem, Eric¹⁵ (AUTHOR), Tabernero, Josep¹⁶ (AUTHOR), Li, Kan¹⁷ (AUTHOR), Shih, Chie-Schin¹⁷ (AUTHOR), Bhagia, Pooja¹⁷ (AUTHOR), Rha, Sun Young¹³ (AUTHOR)

Superior Title: Lancet. Dec2023, Vol. 402 Issue 10418, p2197-2208. 12p.

Subject Terms: TRASTUZUMAB, POISONS, ADVERSE health care events, CLINICAL trials, GASTROPARESIS, PROGRESSION-free survival

Company/Entity: MERCK & Co. Inc. 001317064 MRK

Authors: Langreth, Robert (AUTHOR)

Superior Title: Bloomberg.com. 4/25/2024, pN.PAG-N.PAG. 1p.

Subject Terms: *STANDARD & Poor's 500 Index, CANCER treatment, TRIPLE-negative breast cancer

Company/Entity: MERCK KGaA , MERCK & Co. Inc. 001317064 MRK

Authors: Shitara, Kohei¹ (AUTHOR) kshitara@east.ncc.go.jp, Rha, Sun Young^2,3 (AUTHOR), Wyrwicz, Lucjan S⁴ (AUTHOR), Oshima, Takashi⁵ (AUTHOR), Karaseva, Nina⁶ (AUTHOR), Osipov, Mikhail⁷ (AUTHOR), Yasui, Hisateru⁸ (AUTHOR), Yabusaki, Hiroshi⁹ (AUTHOR), Afanasyev, Sergey¹⁰ (AUTHOR), Park, Young-Kyu¹¹ (AUTHOR), Al-Batran, Salah-Eddin^12,13 (AUTHOR), Yoshikawa, Takaki¹⁴ (AUTHOR), Yanez, Patricio¹⁵ (AUTHOR), Dib Bartolomeo, Maria¹⁶ (AUTHOR), Lonardi, Sara¹⁷ (AUTHOR), Tabernero, Josep¹⁸ (AUTHOR), Van Cutsem, Eric¹⁹ (AUTHOR), Janjigian, Yelena Y²⁰ (AUTHOR), Oh, Do-Youn²¹ (AUTHOR), Xu, Jianming²² (AUTHOR)

Superior Title: Lancet Oncology. Feb2024, Vol. 25 Issue 2, p212-224. 13p.

Subject Terms: *INTERACTIVE voice response (Telecommunication), *IMMUNE checkpoint inhibitors, *STOMACH cancer, *GASTROPARESIS, *RECTAL cancer, *PEMBROLIZUMAB, *GASTRIC bypass, *ADVERSE health care events, *RADIOTHERAPY

Company/Entity: MERCK & Co. Inc. 001317064 MRK

Superior Title: Merck & Co., Inc. MarketLine Company Profile. 12/20/2021, p1-74. 74p.

Subject Terms: *HEALTH care industry

Geographic Terms: UNITED States

Company/Entity: MERCK & Co. Inc. 001317064 MRK

Superior Title: Merck & Co., Inc. SWOT Analysis. 12/20/2021, p1-6. 6p.

Subject Terms: *PHARMACEUTICAL industry, *SWOT analysis

Geographic Terms: NEW Jersey

Company/Entity: MERCK & Co. Inc. 001317064 MRK

Authors: Lauerman, John (AUTHOR)

Superior Title: Bloomberg.com. 2/6/2024, pN.PAG-N.PAG. 1p.

Subject Terms: HEALTH of pets, ANIMAL health

Company/Entity: MERCK KGaA , MERCK & Co. Inc. 001317064 MRK

Authors: Lauerman, John (AUTHOR)

Superior Title: Bloomberg.com. 2/6/2024, pN.PAG-N.PAG. 1p.

Subject Terms: *STOCK prices, *PRICES, ANIMAL health

Company/Entity: MERCK KGaA , MERCK & Co. Inc. 001317064 MRK

Authors: Koons, Cynthia (AUTHOR), Davis, Michelle F. (AUTHOR), Langreth, Robert (AUTHOR)

Superior Title: Bloomberg.com. 1/8/2024, pN.PAG-N.PAG. 1p.

Subject Terms: *PHARMACEUTICAL industry, SMALL cell lung cancer

Company/Entity: MERCK KGaA , MERCK & Co. Inc. 001317064 MRK

Authors: Cattan, Nacha

Superior Title: Bloomberg.com. 1/4/2024, p1-1. 1p.

Subject Terms: NON-alcoholic fatty liver disease, OBESITY

Company/Entity: MERCK KGaA , MERCK & Co. Inc. 001317064 MRK

Authors: Douma, Li-Anne H¹ (AUTHOR), Lalezari, Ferry² (AUTHOR), van der Noort, Vincent³ (AUTHOR), de Vries, Jeltje F³ (AUTHOR), Monkhorst, Kim⁴ (AUTHOR), Smesseim, Illaa¹ (AUTHOR), Baas, Paul¹ (AUTHOR), Schilder, Bodien¹ (AUTHOR), Vermeulen, Marrit³ (AUTHOR), Burgers, Jacobus A¹ (AUTHOR) s.burgers@nki.nl, de Gooijer, Cornedine J¹ (AUTHOR)

Superior Title: Lancet Oncology. Nov2023, Vol. 24 Issue 11, p1219-1228. 10p.

Subject Terms: *PLEURA diseases, *LYMPHOPENIA, *MESOTHELIOMA, *ADVERSE health care events, *PEMBROLIZUMAB, *MYOCARDIAL infarction

Geographic Terms: AMSTERDAM (Netherlands)

Company/Entity: MERCK & Co. Inc. 001317064 MRK

Authors: Meulman, Jessica¹ (AUTHOR) jessica.meulman@adium.com.br, Davanço, Marcelo Gomes¹ (AUTHOR) debora.vianna@adium.com.br, Vianna, Débora Renz Barreto¹ (AUTHOR) thalita.silva@adium.com.br, da Silva, Thalita Martins¹ (AUTHOR) celso.vespasiano@adium.com.br, Costa, Fernando² (AUTHOR) fcosta@raffo.com.ar, Pacheco, Fernando Bastos Canton³ (AUTHOR) fernando.pacheco@synvia.com, de Oliveira, Milla Emke³ (AUTHOR) milla.oliveira@synvia.com, Vespasiano, Celso Francisco Pimentel¹ (AUTHOR)

Superior Title: Pharmaceutics. Nov2023, Vol. 15 Issue 11, p2569. 11p.

Subject Terms: *CYCLOOXYGENASE 2 inhibitors, *GENERIC products, *IN vivo studies, *COMMERCIAL product testing, *DRUG administration

Geographic Terms: BRAZIL

Company/Entity: MERCK & Co. Inc. 001317064 MRK

Authors: Marathe, Dhananjay D.¹ (AUTHOR), Jauslin, Petra M.² (AUTHOR), Kleijn, Huub Jan² (AUTHOR), de Miranda Silva, Carolina¹ (AUTHOR), Chain, Anne¹ (AUTHOR) anne.chain@merck.com, Bateman, Thomas¹ (AUTHOR), Shaw, Peter M.¹ (AUTHOR), Abraham, Anson K.¹ (AUTHOR), Kauh, Eunkyung A.¹ (AUTHOR), Liu, Yanfang¹ (AUTHOR), Perini, Rodolfo F.¹ (AUTHOR), de Alwis, Dinesh P.¹ (AUTHOR), Jain, Lokesh¹ (AUTHOR)

Superior Title: CPT: Pharmacometrics & Systems Pharmacology. Oct2023, Vol. 12 Issue 10, p1499-1510. 12p.

Subject Terms: *ETHNICITY, *PHARMACOKINETICS, *RENAL cell carcinoma, *HYPOXIA-inducible factors, *CENTRAL nervous system, *RACE

Company/Entity: MERCK & Co. Inc. 001317064 MRK

Authors: Vandamme, Erick J¹ (AUTHOR) erick.vandamme@ugent.be

Superior Title: Journal of Industrial Microbiology & Biotechnology. Dec2021, Vol. 48 Issue 9/10, p1-6. 6p.

Subject Terms: *INDUSTRIAL microbiology, *BIOTECHNOLOGY, *INDUSTRIAL capacity, *GREEN technology, *EARTH (Planet), *NANOBIOTECHNOLOGY

Company/Entity: MERCK & Co. Inc. 001317064 MRK

Authors: Büssgen, Melanie¹ (AUTHOR) melanie.buessgen@uni-hamburg.de, Büssgen, Marcel A.² (AUTHOR)

Superior Title: Journal of Pharmaceutical Policy & Practice. 9/28/2023, Vol. 16 Issue 1, p1-12. 12p.

Subject Terms: *BUSINESS planning, *BUSINESS development, *REGULATORY approval, *DATABASES, *PIPELINE failures, *CLINICAL trials

Company/Entity: MERCK & Co. Inc. 001317064 MRK

Superior Title: Biotechnology Industry Profile: Global. Dec2019, p1-52. 52p.

Subject Terms: *BIOTECHNOLOGY industries

Company/Entity: MERCK & Co. Inc. 001317064 MRK, AMGEN Inc. 039976196 AMGN, NOVARTIS AG 001221845 NVS, SANOFI SA

Superior Title: Merck & Co., Inc. MarketLine Company Profile. 1/10/2020, p1-62. 62p.

Subject Terms: *HEALTH care industry

Geographic Terms: UNITED States

Company/Entity: MERCK & Co. Inc. 001317064 MRK